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Induced pluripotent stem cell (iPSC) tech-
nology has three major clinical applica-
tions in clinics: toxicology, drug screening,
and regenerative medicine. Cardiac myo-
cytes derived fromSCs have already been
used in pharmaceutical companies to pre-
dict cardiac toxicity of drug candidates.
Similar approach can be applied to other
types of cells derived from iPSCs.
Inmyopinion, themost promising appli-
cation of iPSCs resides in drug screening.
iPSCs reprogrammed from patients’ so-
matic cells can be used to recapitulate
disease processes.More than 100 papers
reporting disease modeling using patient-
derived iPSCs have been published in the
last few years. These include not only
monogenicdiseases suchasamyotrophic
lateral sclerosis, but also polygenic dis-
eases such as Alzheimer’s disease.
I expect that several effective drugs will
be developed for currently intractable dis-
eases within the next 10 years. Regenera-
tive medicine is also promising.
Given the cost and time required to
generate iPSCsundergoodmanufacturing
protocol (GMP), pursuing autologous
transplantation may not be practical in the
near future. Therefore, banking of iPSCs
fromHLAhomozygousdonors is anattrac-
tive alternative. A collection of 100 donors
would sufficiently cover 50%–90% of pa-
tients, depending on ethnic groups. To
effectively identify these donors, interna-
tional collaborations are important,
including the standardization of informed
consent fromdonors andGMP regulations
and the cooperation of existing medical
banks such as bone marrow and cord
blood banks.Transplantation
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In the blood and skeletal muscle, lineage-
specific stem cells maintain regenerative
potential throughout life. These cells also
provide a vehicle for cell replacement
therapy in acute injury and degenerative
disease. Indeed, transplant-based therapy
hasalreadybeenapplied in the hematopoi-
etic system; however, toxicity associated
with pretransplant conditioning and post-
transplant graft vs. host disease continues
to restrict its application to only the most
life-threatening conditions. In nonhemato-
poietic tissues, such as skeletal muscle,
cell therapy approaches remain limited
due, in part, to difficulties in isolating rele-
vant regenerative populations and to chal-
lenges in the delivery of these cells, which
do not home naturally via the bloodstream.
Finally, identifying appropriately matched
donors is a significant obstacle for trans-
plantation in general, underscoring the
need for new methods to derive ‘‘cor-
rected’’ cells from autologous sources.
Yet although these challenges clearly
represent substantial hurdles, recent dis-
coveries are bringing game-changing in-
sights and technologies. Most notably,
remarkable advances in genome editing
now promise the ability to specifically and
selectively modify genomic sequences in
patient stem cells to correct inborn muta-
tionsand toenablepatients toserveas their
own donors for autologous therapy. In
addition, novel approaches to target stem
cell niches, specify patient-specific regen-
erative cells from reprogrammed pluripo-
tent cells, and engineer stem cell migration
offer hope for innovative solutions to recal-
citrant problems. These new horizons hold
exciting potential for translating stem cell
biology into new medical treatments.Cell 1Brain in a Dish
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The unavailability of live human brain cells
for research has blocked progress toward
understanding mechanisms behind
mental disorders. Genetic reprogramming
offers a window on these disorders, as it
captures a patient’s genome in relevant
cell types that can be propagated in vitro.
Although still expensive and time con-
suming, this disease in a dish approach
allows progressive time course analyses
of target cells, offering an opportunity to
reveal molecular or pathway alterations
before symptomatic onset. Understand-
ing current pitfalls of this model is crucial
for correct data interpretation and for
extrapolation of conclusions to the human
brain. Creative strategies to collect biolog-
ical material and clinical information from
large patient cohorts are crucial to in-
crease the statistical power that allows
extraction of cellular phenotypes from
the noise resulting from variability intro-
duced by reprogramming and differentia-
tion methods that affect phenotypic read-
outs. For example, through the ‘‘Tooth
Fairy Project,’’ we reprogram cells from
baby teeth of autistic children. We interact
with families by using social networks,
which has dramatically increased the in-
terest in this project over the years. Work-
ingwith largepatient cohorts is also impor-
tant to understand how brain cells derived
from the diverse human genetic back-
ground respond to specific drugs. Addi-
tionally, as several neurodevelopmental
disorders share similar neurological
symptoms, comparisonof in-vitro-derived
patient-specific neural cells provides in-
sights into common trends and unique as-
pects of each neurological disease.53, June 6, 2013 ª2013 Elsevier Inc. 1177
Cardiac Transdifferentiation
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Cellular reprogramming approaches for
cardiovascular (CV) disease hold great
promise to transform our understanding
and treatment of what remains the num-
ber one cause of death. The ability to
reprogram adult cells into iPSCs that can
be differentiated into large numbers of
cardiomyocytes (CMs) represents amajor
technical advance. With this technology,
our field is rapidly modeling myriad
human CV diseases and then using these
cells for drug discovery. Furthermore,
human iPSC-CMs from a range of geno-
types are being developed to screen for
cardiotoxic effects of drugs, which
account for 60% of drug failure.
Use of iPSC-CMs for regenerativemed-
icine will require additional technical
advances, including efficient and consis-
tent maturation, delivery, and integration.
An alternative regenerative approach
involves the direct reprogramming (trans-
differentiation) of resident cardiac fibro-
blasts, which comprise more than 50%
of cells in the human heart. We identified
a combination of developmental cardiac
transcription factors that reprogram adult
cardiac fibroblasts toward a CM fate
in vitro, without passing through a stem
cell state. The same cocktail efficiently re-
programs cardiac fibroblasts in vivo after
cardiac injury in mice, resulting in new
CMs that are mature, are electrically
coupled, and improve cardiac function.
Many questions remain regarding the
mechanism and stochastic nature of
direct reprogramming, but the paradigm
of coaxing endogenous cells to adopt
new fates for regenerative medicine rep-
resents an exciting new frontier for many
cell types.1178 Cell 153, June 6, 2013 ª2013 Elsevier InStem Cell and Diabetes
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Diabetes is a good example of a disease
for which there is an obvious use for stem
cells (SCs)—namely, making functional b
cells to replace those lost (type 1 diabetes)
or dysfunctional (type 2 diabetes).
Although there are nontrivial complicating
factors facing new treatments (immune
rejection in T1D and insulin resistance in
T2D), all diabetics would benefit from hav-
ing more functional b cells.
The goal of making human b cells from
pluripotent SCs is essentially at hand, and
I believe that it will soon be possible to
routinely make large numbers (billions) of
glucose-sensing, insulin-secreting, human
b cells. Transplantation of these cells could
realize the dream of many insulin-depen-
dent diabetics: to be relieved of the daily
finger pricks, insulin injections, and debili-
tating complications of poorly controlled
blood glucose levels. Then the principal
challengeswill be to find amethod toblock
immune rejection of the transplanted cells
and/or to develop an effective encapsula-
tion device that protects the cells.
Finally, I think that a powerful new
phase of SC science will come from
combining different SC derivatives in
immunocompromisedmice. For example,
imagine ‘‘reconstructing’’ human T1D by
using a diabetic’s iPSCs to make pancre-
atic b cells, immune cells (from human
stem cells), and thymic epithelia and
then transplanting all of these key cell
types into a living test tube, the immuno-
deficient NSGmouse. Will the human dis-
ease develop in the same way in every
mouse? Will iPSCs from different patients
show a different developmental pathol-
ogy? Using SCs to ‘‘reconstruct’’ human
diseases may be our best chance to un-
derstand what causes degeneration and
may point to new treatment avenues.c.Cancer Stem Cells
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Many cancers havebeenshown tocontain
particular cells called cancer stem cells
(CSCs), which display a higher ability to
propagate tumor upon transplantation.
However, this assay assesses the poten-
tial of the cells but not necessarily their
actual fate during tumor growth. Lineage-
tracing experiments have been recently
developed to track the fate of tumor cells
within their natural niche, lending to further
support for the existence of CSCs.
There are, however, many questions
that remain unanswered to exploit our
basic knowledge of CSC for therapeutic
applications. Are some markers specific
for CSCs across different patients with
thesame tumorsandamongdifferent can-
cers? Can we predict the clinical outcome
of cancers based on the frequency and
molecular signature of CSCs? Does elimi-
nation of CSC lead to tumor regression?
What are the mechanisms that control
renewal versus differentiation of CSC?
Can we stimulate differentiation of CSCs
or decrease their long-term self-renewing
properties to achieve tumor regression in
human cancers? Are the cells that sustain
tumor growth the same cells that resist
therapy and contribute to tumor relapse?
What are the molecular mechanisms that
mediate resistance of cancer cells to
chemo and radiotherapy? Does targeting
these mechanisms lead to a better,
more complete, and long-lasting clinical
response?
Clearly, more studies are needed to
rigorously test the CSC hypothesis in
different cancers and their importance in
resistance to therapy. Addressing these
open questions should provide new hints
tobetter understand themechanismscon-
trolling CSCs and to develop new strate-
gies to target thesecells in clinical settings.
Secrets in the Egg
John Gurdon
Cambridge University
As development proceeds from embryo
to adult, the differentiated state of cells
becomes increasingly stable; fortunately
it is very unusual for cells committed to
one lineage to switch to another. Never-
theless a change to an embryonic state
or to another kind of differentiation can
be induced experimentally by somatic
cell nuclear transfer, cell fusion, or tran-
scription factor overexpression, as in
iPSCs. However, such induced changes
take place only at a very low frequency
and are usually imperfect. I believe that a
very important question asks by what
mechanisms these induced changes
take place. It seems very likely that re-
programming by nuclear transfer to eggs
uses the same route as for sperm after
fertilization. The sperm is a highly special-
ized cell, which is changed in a very short
time to the entirely different male pronu-
cleus, with 100% efficiency after normal
fertilization. This depends on natural com-
ponents of the egg. If we could identify
these egg components and their mode
of action, this information might be used
to alter somatic cells before nuclear trans-
fer so that their reprogramming by eggs to
an embryonic state is much more effi-
cient. It should then require less prolifera-
tion in vitro for the resulting embryonic
stem cells, reducing errors that might
occur and thus yield a higher quality of
cells for replacement therapy in the clinic.Power of Tissue Culture
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In 1975, Howard Green and coworkers
pioneered the culturing of human
epidermal keratinocytes under conditions
in which they could be maintained and
passaged for hundreds of generations.
They succeeded by realizing that epithe-
lial cells rely upon mesenchymal factors
for self-renewal and survival. Green also
showed that, after long-term passage,
epidermal stem cells from a patient could
be cultured to restore skin over burned re-
gions. These principles have been adapt-
ed and/or modified, most notably to grow
corneal cells to treat blindness and to cul-
ture embryonic and intestinal stem cells.
By parroting temporal environments
experienced by embryonic cells as they
diversify into tissues, the strategy is
currently being exploited to achieve line-
age-specific differentiation of iPSCs.
There seems to be no end in sight to the
variations on this theme. Will we soon be
able to culture hair follicles, motor or
dopaminergic neurons, cardiac muscle
cells, or retinal cells for regenerative med-
icine purposes? Although these applica-
tions seem closer to our reach than ever
before, the natural microenvironments
that cells thrive in are not always easily
recapitulated in vitro. Added hurdles are
posed in coaxing progenitors that nor-
mally don’t churn out tissue to do so.
The Holy Grail to advance stem cell thera-
peutics now rests in the court of basic sci-
entists who seek to unravel the crosstalk
between stem cells, their niches, and their
progeny.Cell 1Challenges Ahead
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Crucial technical challenges that stood in
the way of using iPSCs for better under-
standing human disease have been
resolved, including the generation of vec-
tor-free iPSCs, efficient gene-editing
methods, and better-defined culture envi-
ronments. Yet, I see four major hurdles
that need to be overcome before the
iPSC technology will be a standard
approach for studying complex human
diseases that will be used for routine clin-
ical application.
(1) Though the developmental potential
of iPSCs can be stringently defined in
mouse, what are the most appropriate
criteria to define quality of human iPSCs?
(2) Another crucial issue is the choice of
a control: because the differentiation
potential between individual iPSC or
ESC lines varies greatly, one cannot be
sure that a subtle phenotype in a patient’s
iPSC is disease relevant rather than due to
system immanent variation. The develop-
ment of efficient gene-editing methods
may allow the generation of isogenic pairs
of disease-specific and control cells even
for polygenic diseases. (3) Arguably the
most pressing issue for producing a dis-
ease-relevant phenotype in the dish is
how to efficiently induce iPSCs to
generate self-renewing precursor cells
such as hematopoietic stem cells and
mature functional cells such as insulin-
producing b cells. (4) Finally, are
terminally differentiated or self-renewing
precursor cells the most appropriate
therapeutic cells in the routine clinical
setting?
Given the breathtaking progress in the
field, we can be optimistic that these tech-
nical hurdles will be resolved in the fore-
seeable future.53, June 6, 2013 ª2013 Elsevier Inc. 1179
